Avricore Health Inc. Files May 2025 6-K Report
Ticker: AVCRF · Form: 6-K · Filed: Jun 5, 2025 · CIK: 1355736
| Field | Detail |
|---|---|
| Company | Avricore Health INC. (AVCRF) |
| Form Type | 6-K |
| Filed Date | Jun 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer, corporate-update
Related Tickers: AVRX
TL;DR
AVRICORE HEALTH (AVRX) filed its May 6-K, confirming 20-F annual report filings.
AI Summary
Avricore Health Inc. filed a Form 6-K for the month of May 2025, reporting as a foreign private issuer. The company, formerly known as Vanc Pharmaceuticals Inc. and NUVA Pharmaceuticals Inc., is incorporated in A1 and has its principal executive offices at 1120-789 West Pender St, Vancouver, BC, V6C 1H2. The filing indicates that Avricore Health Inc. files its annual reports under Form 20-F.
Why It Matters
This filing provides routine updates for investors and stakeholders regarding Avricore Health Inc.'s status as a foreign private issuer and its reporting practices.
Risk Assessment
Risk Level: low — This is a routine 6-K filing providing standard corporate information and reporting status, with no new material financial or operational developments disclosed.
Key Numbers
- 000-51848 — Commission File Number (Identifies the SEC filing)
Key Players & Entities
- Avricore Health Inc. (company) — Registrant
- Vanc Pharmaceuticals Inc. (company) — Former company name
- NUVA Pharmaceuticals Inc. (company) — Former company name
- Form 20-F (document) — Annual report filing type
- Form 6-K (document) — Report type
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the registrant makes or is required to make public in its home country, files or is required to file with a stock exchange, or distributes or is required to distribute to its security holders.
What is the reporting period for this Form 6-K?
This Form 6-K is for the month of May 2025.
Does Avricore Health Inc. file annual reports under Form 20-F or 40-F?
Avricore Health Inc. indicates it files annual reports under cover of Form 20-F.
What are the former names of Avricore Health Inc. mentioned in the filing?
The filing lists former company names as Vanc Pharmaceuticals Inc. and NUVA Pharmaceuticals Inc.
What is the principal executive office address for Avricore Health Inc.?
The principal executive office is located at 1120-789 West Pender St, Vancouver, BC, V6C 1H2.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 5, 2025 regarding Avricore Health Inc. (AVCRF).